In a reversal, investigators for a trial comparing Biotronik‘s bioresorbable, drug-eluting Orsiro stent and Biosensors‘ BioFreedom drug-eluting stent reported this week that Biosensors’ device did not meet the criteria for noninferiority. The researchers said that while preparing the study for publication in a journal, they discovered a statistical error that ultimately changed the trial’s conclusion. The results […]
Biosensors International launches US pivotal for BioFreedom DCS
Biosensors International said today it enrolled the 1st patient in a pivotal US study of its BioFreedom drug-coated stent. The Singapore-based company’s Leaders Free II study is an ongoing trial examining the use of the BioFreedom DCS in patients at high bleeding risk who receive an ultra-short dual anti-platelet drug regimen of 1 per month. “We […]
Cardinal Health’s Cordis gets back in the drug-eluting stent game with Biosensors deal
Cardinal Health (NYSE:CAH) said today that its Cordis subsidiary is getting back into the drug-eluting stent game via an overseas distribution agreement with Biosensors International (PINK:BSNRY). The deal calls for Cordis to sell the BioFreedom, BioMatrix NeoFlex, BioMatrix Alpha and Chroma stents made by Biosensors in Europe, the Middle East, Australia and New Zealand. Cordis said it plans to gradually […]
Biosensors’ new CEO is Abbott, Guidant vet | Personnel Moves
Biosensors lands FDA OK to launch U.S. trial of drug-eluting stent
Biosensors lowers guidance on weakness in stent market
Abbott, Boston Scientific pay almost no taxes in Ireland despite billions in profits | Wall Street Beat
Biosensors International wins CE Mark for latest line of drug-eluting stents
Biosensors International (PINK:BSNRY) said it won a green light from European regulators for its BioMatrix NeoFlex drug-eluting stent, the latest in its DES line.
Stung by widening losses, Accuray plans $75M debt offering | Wall Street Beat
Accuray (NSDQ:ARAY) plans to issue $75 million worth of convertible senior notes as it gears up to restructure its business after a year of widening losses.
The Sunnyvale, Calif.-based medical device company said it will use the proceeds from the offering of debt due Feb. 1, 2018, to shore up its balance sheet.
Biosensors lands CE Mark for BioFreedom polymer-free stent
TCT 2012: Drug-eluting and semi-resorbable stents hold their own
Stent makers came out in force for the Transcatheter Cardiovascular Therapeutics meeting in Miami this week, touting results of clinical studies of next-generation drug-eluting stents and new designs with bioresorbable polymers.
MassDevice Network
@MassDevice
LinkedIn
YouTube